According to a recent LinkedIn post from Resilience Care, the company is present at the Société Française d’Hématologie congress at the Palais des Congrès in Paris from March 25 to 27. The post invites attendees to visit stand 15 to discuss telemonitoring and new approaches to follow-up care for hematology patients.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post highlights Resilience Care’s active engagement with hematology professionals and its focus on digital or remote patient-monitoring solutions. For investors, this visibility at a specialized medical congress may support business development opportunities, strengthen relationships with clinicians, and potentially drive adoption of its platforms in a niche but complex therapeutic area.
By emphasizing tele-surveillance and innovative follow-up models, the post suggests that Resilience Care is positioning itself within the broader trend toward outpatient and home-based care in oncology and hematology. If the company can convert this presence into pilot projects or partnerships with hospitals and specialists, it could enhance its competitive positioning in the French and potentially wider European digital health market.
The participation of multiple named team members also points to a coordinated commercial and scientific presence rather than a minimal marketing appearance. This may indicate ongoing investment in field activities aimed at accelerating market penetration, which, over time, could translate into higher recurring revenues if its telemonitoring solutions gain traction in hematology care pathways.